Septerna, Inc.
SEPN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001984086
In the last 90 days, Septerna, Inc. insiders filed 0 open-market purchases and 8 sales; 153 institutions reported holding it in 13F filings for Q2 2026, worth $1.59B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Septerna, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 8 filings
- 5 insiders, $72.5M in total
- Insiders trading
- 5
- Net value
- −$72.5M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Septerna, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Patni Rajiv | Chief Medical Officer | – | Sep 10, 2026 | 1 |
| Long Daniel D. | SVP, Drug Discovery | 96,412 | Sep 3, 2026 | 6 |
| Third Rock Ventures V, L.P. | 10% Owner | 6,068,391 | Aug 14, 2026 | 1 |
| Third Rock Ventures VI, L.P. | 10% Owner | 6,068,391 | Aug 14, 2026 | 1 |
| Third Rock Ventures GP V, LP | 10% Owner | 6,068,391 | Aug 14, 2026 | 1 |
| Third Rock Ventures GP VI, L.P. | 10% Owner | 6,068,391 | Aug 14, 2026 | 1 |
| TRV GP VI, LLC | 10% Owner | 6,068,391 | Aug 14, 2026 | 1 |
| TRV GP V, LLC | 10% Owner | 6,068,391 | Aug 14, 2026 | 1 |
| RA Capital Healthcare Fund LP | Director, 10% Owner | 725,443Indirect | Aug 14, 2026 | 2 |
| Ra Capital Management, L.P. | Director, 10% Owner | 725,443Indirect | Aug 14, 2026 | 2 |
| Kolchinsky Peter | Director, 10% Owner | 725,443Indirect | Aug 14, 2026 | 2 |
| Shah Rajeev M. | Director, 10% Owner | 725,443Indirect | Aug 14, 2026 | 2 |
| RA Capital Nexus Fund III, L.P. | Director | 725,443Indirect | Aug 14, 2026 | 2 |
| Bhatt Elizabeth | President and COO | 174,209 | Aug 13, 2026 | 5 |
| Sharp Shalini | Director | – | Jun 30, 2026 | 1 |
| Tong Jeffrey K | Director | – | Jun 30, 2026 | 1 |
| Gottesdiener Keith Michael | Director | – | Jun 30, 2026 | 2 |
| Ezekowitz Alan | Director | 117,420 | Jun 30, 2026 | 1 |
| Coulie Bernard | Director | – | Jun 30, 2026 | 1 |
| Simson Jake | Director | – | Jun 30, 2026 | 1 |
| Bassan Abraham | Director | – | Jun 30, 2026 | 1 |
| Shaikhly Samira | Chief People Officer | 793 | Jun 30, 2026 | 6 |
| Labrucherie Gil M | Chief Financial Officer | 40,000Indirect | Feb 10, 2026 | 1 |
| Wilson Mark Andrew | Chief Legal Officer | – | Feb 10, 2026 | 1 |
| Kim Jae B. | Chief Medical Officer | – | Feb 10, 2026 | 1 |
| Klein Uwe | SVP, Biological Sciences | 23,008 | Feb 10, 2026 | 1 |
| Finer Jeffrey | Chief Executive Officer | 826,907 | Feb 10, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 (view filing)7:01 PM ET | Sep 1 | 2 days | Long Daniel D.SVP, Drug Discovery | SSale | −3.33K | $37.83 | −$126.1K | −3.3%96.4K after | 10b5-1 |
| Aug 14, 2026 (view filing)5:44 PM ET | Aug 12 | 2 days | Third Rock Ventures V, L.P. and 5 others10% Owner | SSale | +147.2K | $50.27 | +$7.40M | +2.5%6.07M after | 2 lots10b5-1 |
| Aug 14, 2026 (view filing)5:11 PM ET | Aug 12 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | SSale | −1.49M | $42.50 | −$63.5M | −67.3%725.4K after | 2 lots |
| Aug 13, 2026 (view filing)7:00 PM ET | Aug 11 | 2 days | Bhatt ElizabethPresident and COO | SSale | −25.0K | $44.00 | −$1.10M | −12.5%174.2K after | 10b5-1 |
| Aug 5, 2026 (view filing)7:00 PM ET | Aug 3 | 2 days | Long Daniel D.SVP, Drug Discovery | SSale | −3.33K | $34.47 | −$114.9K | −3.3%96.4K after | 2 lots10b5-1 |
| Jul 17, 2026 (view filing)7:00 PM ET | Jul 15 | 2 days | Bhatt ElizabethPresident and COO | SSale | −4.00K | $33.99 | −$136.0K | −2.2%174.2K after | 10b5-1 |
| Jul 2, 2026 (view filing)7:00 PM ET | Jul 1 | 1 day | Long Daniel D.SVP, Drug Discovery | SSale | −3.33K | $34.36 | −$114.5K | −3.3%96.4K after | 2 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 29 | 1 day | Shaikhly SamiraChief People Officer | SSale | −2.18K | $35.18 | −$76.6K | −73.3%793 after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Long Daniel D.SVP, Drug Discovery | SSale | −15.0K | $35.51 | −$532.6K | −13.5%96.4K after | 2 lots10b5-1 |
| Jun 16, 2026 (view filing) | Jun 12 | 4 days | Shaikhly SamiraChief People Officer | SSale | −6.25K | $35.08 | −$219.3K | −88.7%793 after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Shaikhly SamiraChief People Officer | SSale | −5.93K | $28.92 | −$171.7K | −88.2%793 after | 3 lots10b5-1 |
| May 28, 2026 (view filing) | May 26 | 2 days | Shaikhly SamiraChief People Officer | SSale | −11.8K | $30.06 | −$354.6K | −93.7%793 after | 10b5-1 |
| Apr 17, 2026 (view filing) | Apr 15 | 2 days | Bhatt ElizabethPresident and COO | SSale | −4.00K | $24.34 | −$97.4K | −2.2%174.2K after | 3 lots10b5-1 |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Shaikhly SamiraChief People Officer | SSale | −70.5K | $28.10 | −$1.98M | −98.9%793 after | 2 lots10b5-1 |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Bhatt ElizabethPresident and COO | SSale | −4.00K | $28.96 | −$115.9K | −2.2%174.2K after | 2 lots10b5-1 |
| Nov 13, 2025 (view filing) | Nov 10 | 3 days | Long Daniel D.SVP, Drug Discovery | SSale | −3.50K | $18.06 | −$63.2K | −3.6%92.9K after | |
| Mar 10, 2025 (view filing) | Mar 7 | 3 days | Ezekowitz AlanDirector | PPurchase | +13.3K | $6.93 | +$92.3K | +12.8%117.4K after | |
| Mar 6, 2025 (view filing) | Mar 4-6 | 2 days | Ezekowitz AlanDirector | PPurchase | +86.7K | $5.95 | +$515.9K | +497.6%104.1K after | 3 lots |
| Feb 27, 2025 (view filing) | Feb 25-27 | 2 days | Finer JeffreyCEO and President | PPurchase | +17.0K | $5.71 | +$97.0K | +2.3%771.9K after | 3 lots |
| Feb 27, 2025 (view filing) | Feb 25-27 | 2 days | Labrucherie Gil MChief Financial Officer | PPurchase | +10.0K | $5.69 | +$56.9K | +33.3%40.0K after | 2 lots |
| Feb 26, 2025 (view filing)4:15 PM ET | Feb 24 | 2 days | Third Rock Ventures V, L.P. and 5 others10% Owner | PPurchase | +18.9K | $6.00 | +$113.1K | +0.4%4.21M after | |
| Feb 24, 2025 (view filing)4:15 PM ET | Feb 20-21 | 4 days | Third Rock Ventures V, L.P. and 5 others10% Owner | PPurchase | +1.04M | $5.93 | +$6.17M | +33.0%4.19M after | 2 lots |
| Feb 21, 2025 (view filing) | Feb 19-21 | 2 days | Labrucherie Gil MChief Financial Officer | PPurchase | +30.0K | $5.75 | +$172.4K | New position30.0K after | 3 lots |
| Oct 30, 2024 (view filing)6:12 PM ET | Oct 28 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchase | +4.17M | $18.00 | +$75.1M | New position1.47M after | 2 lots |
| Oct 28, 2024 (view filing)4:53 PM ET | Oct 28 | Same day | Third Rock Ventures V, L.P. and 5 others10% Owner | PPurchase | +370.5K | $18.00 | +$6.67M | +6.3%6.22M after | |
| Oct 28, 2024 (view filing)4:53 PM ET | Oct 28 | Same day | Third Rock Ventures V, L.P. and 5 others10% Owner | PPurchase | +279.5K | $18.00 | +$5.03M | +9.7%3.15M after |